Details

Mitochondria-targeting moieties based on N-tethered pyridinium cations
ID Džajić, Ivan (Author), ID Trunkelj, Natalija (Author), ID Repas, Jernej (Author), ID Kandušer, Maša (Author), ID Smrdel, Lara (Author), ID Pajk, Stane (Author), ID Žiberna, Lovro (Author), ID Mlinarič-Raščan, Irena (Author), ID Markelc, Boštjan (Author), ID Božič, Tim (Author), ID Omerzel, Maša (Author), ID Jesenko, Tanja (Author), ID Čemažar, Maja (Author), ID Kološa, Katja (Author), ID Žegura, Bojana (Author), ID Virant, Miha (Author), ID Lozinšek, Matic (Author), ID Tomašič, Tihomir (Author), ID Peterlin-Mašič, Lucija (Author), ID Cotman, Andrej Emanuel (Author)

.pdfPDF - Presentation file, Download (23,84 MB)
MD5: E04E9287946491F88B420B68B6F38509
URLURL - Source URL, Visit https://onlinelibrary.wiley.com/doi/10.1002/anie.7158257 This link opens in a new window

Abstract
Mitochondria-targeting moieties (MTMs) are molecular fragments designed to deliver covalently tethered functional cargo to mitochondria, providing a modular strategy for chemical biology tools, imaging agents, and mitochondria-targeted therapies. Phosphonium- or nitrogen cation-based MTMs are not inert vectors and exhibit intrinsic bioactivity on mitochondrial and cellular levels to various extents. Here, we systematically evaluated a panel of N+-based cations to determine how structural features influence subcellular distribution and inherent bioactivity. Live-cell imaging of fluorescent dye conjugates revealed that 3,5-diphenylpyridinium (DPPy+) exhibits cellular uptake and mitochondrial targeting comparable to the benchmark triphenylphosphonium (TPP+), whereas conjugates with unsubstituted pyridinium preferentially accumulate in lysosomes. Profiling of inert cargo derivatives showed that DPPy+ has lower intrinsic activity on mitochondrial membrane potential and oxidative phosphorylation, as well as on cellular respiration and viability than TPP+. The combination of efficient mitochondrial delivery and low intrinsic bioactivity translated to bioactive cargo: a Kv1.3 inhibitor conjugate with DPPy+ induced apoptosis in cancer cell lines and demonstrated improved cancer selectivity relative to the TPP+ conjugate in pancreatic organoid models. These results position lipophilic pyridinium cations as effective TPP+ surrogates with enhanced biocompatibility for mitochondria-targeted therapeutic and diagnostic agents, while revealing the structure-dependent competing lysosomal accumulation of permanent nitrogen cations.

Language:English
Keywords:cancer, cations, fluorescentprobes, medicinal chemistry, mitochondria
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2026
Year:2026
Number of pages:Str. 1-13
Numbering:Vol. , iss. , [article no.] e7158257
PID:20.500.12556/RUL-184316 This link opens in a new window
UDC:615.4:54:616-006
ISSN on article:1521-3773
DOI:10.1002/anie.7158257 This link opens in a new window
COBISS.SI-ID:279001347 This link opens in a new window
Publication date in RUL:03.07.2026
Views:43
Downloads:31
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Angewandte Chemie : international edition
Shortened title:Angew. Chem.
Publisher:Wiley-VCH
ISSN:1521-3773
COBISS.SI-ID:21810181 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:kationi, fluorescentne sonde, medicinska kemija, mitohondriji

Projects

Funder:Other - Other funder or multiple funders
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J7-4635-2022
Name:MitoCan - Predklinični razvoj novih zaviralcev mitohondrijskih ionskih kanalov za zdravljenje raka

Funder:Other - Other funder or multiple funders
Funding programme:University of Ljubljana
Project number:SN-ZRD/22-27/510
Name:University of Ljubljana start-upprogramme

Funder:Other - Other funder or multiple funders
Funding programme:Slovenian Ministry of Higher Education, Science, and Innovation
Project number:/
Name:/

Funder:EC - European Commission
Project number:P20.05187RI-SI-EATRIS
Name:European Regional Development Fund
Acronym:ERDF

Funder:EC - European Commission
Project number:950625
Name:Challenging the Oxidation-State Limitations of the Periodic Table via High-Pressure Fluorine Chemistry
Acronym:HiPeR-F

Funder:HRZZ - Croatian Science Foundation
Funding programme:Croatian Science Foundation (CSF)
Project number:IP-2022-10-2634
Name:The environmental fate of pharmaceuticals of concern: experimental and computational study of degradation products and their ecotoxicological properties

Funder:SNSF - Swiss National Science Foundation
Project number:27271
Name:Monographie historique du Val d'Anniviers

Funder:Other - Other funder or multiple funders
Funding programme:Italian Association for Cancer Research
Project number:fellowship 33493
Name:/
Acronym:/

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back